MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$4,856,051
Operating loss
-$4,561,200
Total other income
(expense)
-$294,851
Grant income
$22,174
Interest income
$147
Total operating
expenses
$4,561,200
Change in fair value of
warrant liabilities
$279,161
Currency exchange gain
(loss)
-$32,051
Interest expense
$5,960
Research and development
$3,161,064
General and
administrative
$1,400,136
Back
Back
Income Statement
source: myfinsight.com
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)